The hydrogen/deuterium-exchange (H/D-Ex) phenomenon is well established as a method for measuring binding interactions between a drug target and a ligand. ExSAR Corp. has developed an automated, rapid, and sensitive H/D-Ex system to rapidly map drug-target interactions in solution, for use in small-molecule drug discovery and also to assist in the stabilization and design of new protein therapeutics.
11 Deer Park Dr., Suite 103
Monmouth Junction, NJ 08852
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The company said it intends to maintain a focus on rare neuromuscular disease with apitegromab but could consider partnering in obesity.
The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
The country’s life sciences investment head tells Scrip that it is business as usual for the sector despite the rumblings from across the Atlantic.
Wales-based group launches with $140m series A.
Highlights from Day Two of the BIO International Convention include BIO officials raising concerns about Trump Administration policies, the future of ACIP, an interview with BI's head of global business development, and FDA Commissioner Martin Makary's view of the FDA-industry relationship.
